Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2- negative breast cancer

PAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal patients with estrogen receptor estrogen receptor-positive (ER+)/ HER2-negative (HER2-) early breast cancer. Low risk patients might not need adj...

Descripción completa

Detalles Bibliográficos
Autores: Fernandez-Martinez, Aranzazu, Pascual, Tomás, Perrone, Giuseppe, Morales Murillo, Serafín, de la Haba, Juan, González-Rivera, Milagros, Galván, Patricia, Zalfa, Francesca, Amato, Michela, Gonzalez, Lucia, Prats, Miquel, Rojo, Federico, Manso, Luis, Paré, Laia, Alonso, Immaculada, Albanell, Joan, Vivancos, Ana, González, Antonio, Matito, Judit, González, Sonia, Fernandez, Pedro, Adamo, Barbara, Muñoz, Montserrat, Viladot, Margarita, Font, Carme, Aya, Francisco, Vidal, Maria, Caballero, Rosalía, Carrasco, Eva, Altomare, Vittorio, Tonini, Giuseppe, Prat, Aleix, Martin, Miguel
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Institución:Universitat de Lleida (UdL)
Repositorio:Repositori Obert UdL
OAI Identifier:oai:repositori.udl.cat:10459.1/70874
Acceso en línea:https://doi.org/10.18632/oncotarget.15748
http://hdl.handle.net/10459.1/70874
Access Level:acceso abierto
Palabra clave:PAM50/Prosigna
Breast cancer
Ki67
Estrogen receptor-positive/HER2-negative
Descripción
Sumario:PAM50/Prosigna gene expression-based assay identifies three categorical risk of relapse groups (ROR-low, ROR-intermediate and ROR-high) in post-menopausal patients with estrogen receptor estrogen receptor-positive (ER+)/ HER2-negative (HER2-) early breast cancer. Low risk patients might not need adjuvant chemotherapy since their risk of distant relapse at 10-years is below 10% with endocrine therapy only. In this study, 517 consecutive patients with ER+/HER2- and node-negative disease were evaluated for Ki67 and Prosigna. Most of Luminal A tumors (65.6%) and ROR-low tumors (70.9%) had low Ki67 values (0-10%); however, the percentage of patients with ROR-medium or ROR-high disease within the Ki67 0-10% group was 42.7% (with tumor sizes ≤2 cm) and 33.9% (with tumor sizes > 2 cm). Finally, we found that the optimal Ki67 cutoff for identifying Luminal A or ROR-low tumors was 14%. Ki67 as a surrogate biomarker in identifying Prosigna low-risk outcome patients or Luminal A disease in the clinical setting is unreliable. In the absence of a well-validated prognostic gene expression-based assay, the optimal Ki67 cutoff for identifying low-risk outcome patients or Luminal A disease remains at 14%.

Similares en LA Referencia